Here is a link to a study published this fall which has important ramifications for older multiple myeloma patients:
By JEAN-LUC HAROUSSEAU, MD
Director, Professor of Hematology, University of Nantes, Nantes/Saint Herblain, France
This isn’t just a link to an abstract. Thanks to Cancer Network.com, you can read the entire study, complete with color graphs and slides. The conclusion:
This finding is particularly important at a time when the place of ASCT in frontline therapy is again being debated even for younger patients. Results obtained with novel agents in patients who are not candidates for ASCT are good enough to justify randomized trials comparing novel agents with or without ASCT as frontline therapy in younger patients . This implies that although ASCT should not be abandoned too early in fit older patients, its role remains undetermined in the era of novel therapies and it should not be proposed outside of a clinical trial.
This is a magnificent study. Well designed, composed, implemented and illustrated. Lots of good information here. It is definitely worth a look. Feel good and keep smiling! Pat